Skip to main content
. 2024 Sep 5;11:1381479. doi: 10.3389/fmed.2024.1381479

Figure 4.

Figure 4

Inhibition of Sema3A protects podocytes from Adriamycin-induced injury. (A) Western blotting assay showing the levels of Sema3A in Adriamycin-induced podocytes. (B) Levels of Sema3A in Control, AN, Control siRNA (siRNASema3A-NC), and siRNASema3A, demonstrating a decrease in protein levels with siRNASema3A. (C) Cell viability of podocytes treated with AN+siRNASema3A and AN+siRNASema3A + rhSema3A (200 ng/mL in culture medium). (D) Podocyte migration area decreased in the siRNASema3A group compared with that in the AN and AN+siRNASema3A + rhSema3A groups, as analyzed using scratch wound assay. Scale bar: 100 μm. (E) Quantitative analysis of migration rates in (D). **p < 0.01 (n = 3). (F) Podocyte migration decreased in the siRNASema3A group compared with that in the AN and AN+siRNASema3A + rhSema3A groups, as confirmed using the Transwell assay. Scale bar: 50 μm. (G) Quantitative analysis of migrated cells in (E). **p < 0.01 (n = 3). (H) Determination of apoptotic podocytes using flow cytometry. (I) Relative apoptosis rate decreased following Adriamycin+siRNASema3A and Adriamycin +siRNASema3A + rhSema3A (200 ng/mL in culture medium) treatments compared with that after AN treatment (n = 3) **p < 0.01.